Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907012 | 0.91 | LMNA (0.49) | LMNAATMKEAP1NFE2L2ESR1 | |
| SCHEMBL4906315 | 0.90 | LMNA (0.46) | LMNAATMKEAP1NFE2L2ESR1 | |
| SCHEMBL4900687 | 0.89 | ESR1 (0.39) | LMNAKEAP1NFE2L2ESR1TSHR | |
| SCHEMBL4906945 | 0.88 | LMNA (0.47) | LMNAATMKEAP1NFE2L2ESR1 | |
| SCHEMBL4906802 | 0.86 | POLB (0.44) | LMNAATMTSHRMAPTALDH1A1 | |
| SCHEMBL4911874 | 0.84 | MAOA (0.43) | LMNAATMKEAP1NFE2L2MAPT | |
| SCHEMBL4908025 | 0.84 | MMP9 (0.42) | LMNAKEAP1NFE2L2ESR1TSHR | |
| SCHEMBL4904039 | 0.84 | KEAP1 (0.47) | LMNAKEAP1NFE2L2TSHRMAPT | |
| SCHEMBL4905972 | 0.83 | LMNA (0.55) | LMNAATMKEAP1NFE2L2ESR1 | |
| SCHEMBL4908351 | 0.82 | LMNA (0.45) | LMNAATMESR1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | LMNA 319/4885ATM 1692/4885KEAP1 810/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | LMNA 319/4885ATM 1692/4885KEAP1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.